International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions.
about
Accumulating evidence supports a taste component for free fatty acids in humansInternational Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligandsAcute Respiratory Distress Syndrome: Role of Oleic Acid-Triggered Lung Injury and InflammationObesity, fatty liver disease and intestinal microbiotaThe perilipin homologue, lipid storage droplet 2, regulates sleep homeostasis and prevents learning impairments following sleep lossThe action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1Novel Structural Approaches to Study GPCR RegulationThe Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune DiseaseInternational Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂The effects of propionate and valerate on insulin responsiveness for glucose uptake in 3T3-L1 adipocytes and C2C12 myotubes via G protein-coupled receptor 41The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsSelective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3Are Short Chain Fatty Acids in Gut Microbiota Defensive Players for Inflammation and Atherosclerosis?The saturated fatty acid, palmitic acid, induces anxiety-like behavior in mice.Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes.The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism.PTH1 receptor is involved in mediating cellular response to long-chain polyunsaturated fatty acids.Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity.Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator.Attenuation of inflammatory and neuropathic pain behaviors in mice through activation of free fatty acid receptor GPR40.Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease?Potential anti-obesogenic properties of non-digestible carbohydrates: specific focus on resistant dextrin.Free fatty acid receptors: structural models and elucidation of ligand binding interactions.An inhibitor of phospholipase A2 group IIA modulates adipocyte signaling and protects against diet-induced metabolic syndrome in ratsGas Chromatography-Mass Spectrometry Analysis of Ulva fasciata (Green Seaweed) Extract and Evaluation of Its Cytoprotective and Antigenotoxic Effects.Free fatty acid receptors: emerging targets for treatment of diabetes and its complications.Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptorEfficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes.Diacylglycerol kinase inhibitor R59022 attenuates conjugated linoleic acid-mediated inflammation in human adipocytes.A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique Gi-functional BiasDrugs or diet?--Developing novel therapeutic strategies targeting the free fatty acid family of GPCRsThe pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonismDeletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets.Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3.The production of nitric oxide, IL-6, and TNF-alpha in palmitate-stimulated PBMNCs is enhanced through hyperglycemia in diabetes.From the gut to the peripheral tissues: the multiple effects of butyrate.Do SCFA have a role in appetite regulation?Low affinity GPCRs for metabolic intermediates: challenges for pharmacologists.Digestive physiology of the pig symposium: G protein-coupled receptors in nutrient chemosensation and gastrointestinal hormone secretion.
P2860
Q22337318-D4B7A65A-5A62-48C5-A99A-0C7F19D1EFD8Q24605072-56C123D0-6A3B-4038-9D1B-6963275B9D34Q26774216-71738BC3-2929-4DBD-9ED1-BEE3767C685BQ26997784-15B94471-5921-48F0-B169-4D75AD4B28C0Q27323420-EA869D16-108D-495A-901B-706CFD3AD83BQ27865233-3ACF153F-99E8-418A-98D9-8962428E5FBCQ28067568-24110C61-1F6C-42DD-A2C7-B0F3C718B808Q28276657-698DBE64-E7C5-4246-A556-4BA76E8D0A7DQ28298445-13F7CAE4-542D-4DD7-8DDB-35969F21940FQ28588479-1DDD8C94-F508-4DFC-B985-6D8185875924Q30486707-23F402E0-CADB-4ADB-8B71-314EDA9BDEF5Q33789758-DE0F339D-F6FA-42EF-A3F1-9CB47A9EB5F2Q33918713-00CC1DD0-BA88-4B11-BC23-1EF57334428DQ34117633-B65A01EA-0079-4421-8908-D302DC94CD16Q34120699-5943C195-AD91-4814-BEFC-0D4E13C28539Q34355154-7A9BCECA-0BA3-406C-87FE-52D9079CEA28Q34540884-A4D8F6E8-1C31-40DF-985B-31B3594A42CAQ35049771-033A11DB-1336-47A5-924E-8F6C4322F097Q35080498-9338705E-805E-4075-9774-0502195DE869Q35117995-2B48B7D2-ACB1-4BBB-A41E-A19F016A31CAQ35132145-974042F0-FC32-40FF-8849-8479C41B2D13Q35568441-888C25F2-977C-482F-B9BC-EEE109809526Q35766268-4CE51740-5D32-4919-BE07-EA9EB9C55C40Q36182494-72EE6E0A-0B16-4A7C-9CBE-F1A28D5F6E26Q36285322-3B1EC880-41E1-42F8-AC9D-A8539E8901AEQ36327956-059D50A7-A5FA-4F48-A044-62AAA424709BQ36335625-CA20D9D6-8703-4095-B459-EBE9EECB2C4DQ36366176-C737AF98-7827-4742-BB19-74B52AF58FFDQ36560412-50B53FB2-E814-4F1C-A2DF-FD6F43253C7FQ36744091-66F13CF6-8AEF-42B7-976F-D5D8194DDCD5Q37227642-B25F4114-CC1F-4ECE-949F-DF20D977182BQ37237145-0034818A-82A1-48E7-8D51-D2D08C4279A3Q37252074-B7F91BA9-24C0-4AD1-BD57-2B7DFD5C87E7Q37400740-DD6FDA80-CBEF-4AD7-A48B-4230E0EC9188Q37589701-2F65C3BF-20B9-4949-8DC5-CEB55378DA7FQ37720287-B1380439-1FD2-4004-BB1C-535E63FA4D24Q37799401-0126A9DA-B34F-4EB1-A667-B34881AED158Q37832302-46FAA3C0-F73D-4019-8098-9EC34F0F414DQ38014830-F5123210-AB89-4E66-AF33-EA30EA80E2E6Q38066461-AB4D8B44-935A-4494-9F88-2CB8DD47A9E0
P2860
International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
International Union of Pharmac ...... pathophysiological functions.
@en
International Union of Pharmac ...... pathophysiological functions.
@nl
type
label
International Union of Pharmac ...... pathophysiological functions.
@en
International Union of Pharmac ...... pathophysiological functions.
@nl
prefLabel
International Union of Pharmac ...... pathophysiological functions.
@en
International Union of Pharmac ...... pathophysiological functions.
@nl
P2093
P921
P356
P1476
International Union of Pharmac ...... pathophysiological functions.
@en
P2093
Graeme Milligan
Leigh A Stoddart
Nicola J Smith
P304
P356
10.1124/PR.108.00802
P577
2008-12-01T00:00:00Z